US Procedure Numbers for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedPro
|出版商||iData Research Inc.||商品編碼||392572|
|出版日期||內容資訊||英文 40 Pages
|美國的糖尿病監測、治療、藥物輸送市場上的治療數量 US Procedure Numbers for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedPro|
|出版日期: 2016年11月01日||內容資訊: 英文 40 Pages||
The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps. Sanofi and Novo Nordisk recently launched next-generation insulin products: insulin glargine U-300 (Toujeo®) and insulin degludec (Tresiba®), respectively. Both of these insulin analogs are "ultra-long-acting" and have an average duration of 24 to 36 hours, which means that patients will only be required to perform once-daily injections. Novo Nordisk is currently developing Ryzodeg®, a premixed insulin analog comprising insulin degludec (Tresiba®) and insulin aspart (NovoLog®), in addition to an "ultra-rapid-acting" insulin analog, which are both expected to be launched during the forecast period. The insulin-dependent patient population is expected to transition to next-generation insulin products and will contribute to the growth of the insulin market and associated insulin delivery markets.
Segments Covered in this Procedure Volume Research
This market study focuses specifically on the volume of procedures. It includes analysis of procedures.
This data outlines the exact growth rates for procedures. If you're interested in seeing the trends in procedures to formulate your market sizing and forecasts this is the most accurate and most affordable way to do it.
About Procedure Volume Research (MedPro)
Our analysts meticulously research for 3 to 4 months to put together a suite of reports, which is a comprehensive analysis on a group of healthcare markets. A MedPro is one portion of that analysis that outlines only the procedure volumes and forecasts for each market in that suite of reports.
This procedural analysis is incorporated in our market size analysis and forecasting which are available when purchasing a MedSuite, MedView or MedCore.
Where Do We Get Our Procedure Data?
Our team of analysts has proprietary data that we've been collecting for over a decade as well as government and private databases like that from CMS and hospital records. By looking at multiple sources we are able to triangulate on orthopedic soft tissue procedure volumes that influence and coincide with our overall market sizing.
Questions This Report will Help You Answer:
What is affecting the volume of procedures?
How many procedures were done in 2016?
How many procedures were done historically?
How many procedures can we expect in 2023 and what is the growth trend?